These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18035428)

  • 1. Potential of antiviral therapy and prophylaxis for controlling RNA viral infections of livestock.
    Goris N; Vandenbussche F; De Clercq K
    Antiviral Res; 2008 Apr; 78(1):170-8. PubMed ID: 18035428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly pathogenic RNA viral infections: challenges for antiviral research.
    Bray M
    Antiviral Res; 2008 Apr; 78(1):1-8. PubMed ID: 18243346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen and vaccine banks: technical requirements and the role of the european antigen bank in emergency foot and mouth disease vaccination.
    Lombard M; Füssel AE
    Rev Sci Tech; 2007 Apr; 26(1):117-34. PubMed ID: 17633297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2'-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus.
    Goris N; De Palma A; Toussaint JF; Musch I; Neyts J; De Clercq K
    Antiviral Res; 2007 Mar; 73(3):161-8. PubMed ID: 17055073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic application of RNA interference against foot-and-mouth disease virus in vitro and in vivo.
    Kim SM; Lee KN; Park JY; Ko YJ; Joo YS; Kim HS; Park JH
    Antiviral Res; 2008 Nov; 80(2):178-84. PubMed ID: 18601955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Foot-and-mouth disease vaccine potency testing: the influence of serotype, type of adjuvant, valency, fractionation method, and virus culture on the dose-response curve in cattle.
    Jamal SM; Bouma A; van den Broek J; Stegeman A; Chénard G; Dekker A
    Vaccine; 2008 Nov; 26(50):6317-21. PubMed ID: 18822336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric foot-and-mouth disease viruses: evaluation of their efficacy as potential marker vaccines in cattle.
    Fowler VL; Paton DJ; Rieder E; Barnett PV
    Vaccine; 2008 Apr; 26(16):1982-9. PubMed ID: 18342409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Foot and mouth disease virus vaccines.
    Rodriguez LL; Grubman MJ
    Vaccine; 2009 Nov; 27 Suppl 4():D90-4. PubMed ID: 19837296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extending the foot-and-mouth disease module to the control of other diseases.
    De Clercq K; Goris N
    Dev Biol (Basel); 2004; 119():333-40. PubMed ID: 15742644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Foot-and-Mouth disease 'vaccination-to-live': possibilities and constraints.
    Roth JA
    Dev Biol (Basel); 2004; 119():267-72. PubMed ID: 15742638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural analysis of foot-and-mouth disease virus 3C protease: a viable target for antiviral drugs?
    Curry S; Roqué-Rosell N; Sweeney TR; Zunszain PA; Leatherbarrow RJ
    Biochem Soc Trans; 2007 Jun; 35(Pt 3):594-8. PubMed ID: 17511659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving perception on the benefits of vaccination as a foot and mouth disease control policy: contributions of South America.
    Bergmann IE; Malirat V; Falczuk AJ
    Expert Rev Vaccines; 2005 Dec; 4(6):903-13. PubMed ID: 16372885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Foot-and-mouth disease control using vaccination: South African experience.
    Brückner GK; Vosloo W; Cloete M; Dungu B; Du Plessis BJ
    Dev Biol (Basel); 2004; 119():51-62. PubMed ID: 15742618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of foot-and-mouth disease virus infections in cell cultures with antisense morpholino oligomers.
    Vagnozzi A; Stein DA; Iversen PL; Rieder E
    J Virol; 2007 Nov; 81(21):11669-80. PubMed ID: 17728223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of protective immunity in swine by immunization with live attenuated recombinant pseudorabies virus expressing the capsid precursor encoding regions of foot-and-mouth disease virus.
    Li X; Liu R; Tang H; Jin M; Chen H; Qian P
    Vaccine; 2008 May; 26(22):2714-22. PubMed ID: 18436351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Mechanisms of Foot-and-Mouth Disease Virus Targeting the Host Antiviral Response.
    Rodríguez Pulido M; Sáiz M
    Front Cell Infect Microbiol; 2017; 7():252. PubMed ID: 28660175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cedivac-FMD can be used according to a marker vaccine principle.
    Chénard G; Selman P; Dekker A
    Vet Microbiol; 2008 Apr; 128(1-2):65-71. PubMed ID: 18035508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus.
    Brehm KE; Kumar N; Thulke HH; Haas B
    Vaccine; 2008 Mar; 26(13):1681-7. PubMed ID: 18313814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-structural protein 3A for differentiation of foot-and-mouth disease infected and vaccinated animals in Haryana (India).
    Kumar N; Sharma R; Kakker NK
    Zoonoses Public Health; 2007; 54(9-10):376-82. PubMed ID: 18035976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral activity of bovine type III interferon against foot-and-mouth disease virus.
    Díaz-San Segundo F; Weiss M; Perez-Martín E; Koster MJ; Zhu J; Grubman MJ; de los Santos T
    Virology; 2011 May; 413(2):283-92. PubMed ID: 21435672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.